Clinical Trials | February 19, 2026
GSK announces breakthrough data showing RSV vaccine cuts hospitalizations in elderly
The data highlights its RSV vaccine cuts hospitalizations in older adults
The data highlights its RSV vaccine cuts hospitalizations in older adults
mNEXSPIKE is the third Moderna vaccine authorized in the European Union, strengthening the Company's respiratory vaccine portfolio in Europe
The FDA’s Center for Biologics Evaluation and Research (CBER) cited Moderna’s choice of a licensed standard-dose flu vaccine as the comparator in its Phase 3 trial, saying it “does not reflect the best-available standard of care.”
Signed Memorandum of Understanding supports "Plan Mexico," Mexico's strategic initiative to build a local mRNA ecosystem and strengthen health security
Hongene will focus on developing and scaling production of key capping reagents—essential components of mRNA therapeutics—emphasizing accessibility, transparency, and global deployment
This license is a key regulatory milestone in advancing Hester's prevention-led poultry healthcare portfolio
This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
DengiAll will be the first indigenous single-shot dengue vaccine in India and is expected to enter the markets by 2027
It is currently the only vaccine authorized by the Drug Controller General of India (DCGI) for active immunization against HEV in adults aged 18 to 65
Subscribe To Our Newsletter & Stay Updated
